Search results
Results from the WOW.Com Content Network
Because of their side effects, methylxanthines are not considered first-choice medicines to treat chronic obstructive pulmonary disease (COPD) . They are prescribed most often for people with COPD who: Still have major difficulty breathing despite using both an inhaled beta2-agonist and an inhaled anticholinergic.
Beta2-agonists are considered first-line therapy for the treatment of stable chronic obstructive pulmonary disease (COPD) with symptoms that come and go (intermittent symptoms). They are used for both short- and long-term relief of symptoms. Beta2-agonists also may be used before exercise to reduce breathing difficulties.
Patients aged < 5 years currently taking medications: asthma control assessment and treatment recommendations. Assess each component over the last 2–4 weeks. The result is based on the score of the most severe component. The treatment recommendation is determined by the level of asthma control. See Table 6 (p.
COPD Assessment Test (CAT) The CAT is a validated tool for assessing the impact on COPD on wellbeing and daily life. There are eight questions on a 1- to 5-point scale, which focus on cough, sputum, breathlessness, chest tightness, confidence, activity, sleep, and energy levels.
Discusses causes and symptoms of COPD. Looks at chronic bronchitis and emphysema, two diseases that are usually a part of COPD.
Interactive tools are designed to help people determine health risks, ideal weight, target heart rate, and more. Interactive Tool: How Does Smoking Increase Your Risk of Heart Att